Amber Weller
0404 772 653
Are you a current client at EPPIC and looking to reduce the dose of your medication
The REDUCE study: Does antipsychotic dose reduction lead to better functional recovery in first episode psychosis
The REDUCE study is testing whether or not reducing the dosage of antipsychotic medication of people recovering from their first episode of psychosis can lead to them having better recovery outcomes.
Currently, antipsychotic treatment is one of the most effective ways to treat psychotic symptoms (i.e. hallucinations and delusions) and prevent relapse in young people who are experiencing psychosis. However, antipsychotics do not meaningfully improve day-to-day functioning. Young people with psychosis are commonly at greater risk of experiencing difficulties in everyday living skills that often impact their ability to find and maintain a job, housing and personal relationships. While antipsychotic treatment is effective and often necessary for symptomatic recovery, there are a number of side effects associated with taking antipsychotics.
This project will investigate whether greater recovery in functioning and better mental and physical health can be achieved through gradually reducing antipsychotic medication earlier in recovery. Gradual reduction of antipsychotic medication will also be combined with an intensive psychosocial intervention package, which will maximise recovery in these areas and aid in relapse prevention.
Anticipated date the enrolment will close: June 2020
Who can take part
- current client of Early Psychosis Prevention and Intervention Centre (EPPIC)
- confirmed diagnosis of first episode of a psychotic disorder
- aged 15-25 years (inclusive)
- greater than 3 months of remission on positive symptoms of psychosis in the first year of antipsychotic treatment at EPPIC
- low suicidality
What is involved for you
- monitoring over 24-month period
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
For more information
Quote reference number
2016.282Carli Ellinghaus
0457 700 250